Anna Smyth

Anna’s experience includes advising:

• Emyria Ltd on an agreement with Aspen Australia for the licensing and commercialisation of EMD-RX5, an ultra-pure CBD capsule aimed at treating symptoms of anxiety and stress in patients with a chronic condition.

• Tivan Ltd on a long-term partnership with CSIRO, including a complex patent licence agreement, to facilitate development and commercialisation of the TIVAN+ critical minerals processing technology.

• Orthocell on a global exclusive IP licence and manufacturing agreement with BioHorizons Implant Systems Inc. about Striate+, a resorbable collagen membrane used for guided bone and guided tissue regeneration procedures.

• UNSW on the important parts of its ongoing involvement with Diraq and Silicon Quantum Computing. These arrangements underpin UNSW’s commercialisation of its patent protected world leading quantum computing technology.

• A G08 university on a project to upgrade its processes and precedents in respect of Research, Grants, Contracts and Commercialisation.

• PIUS Limited LLC on the grant of $60 million in secured funding for Carbon Revolution, a leading global manufacturer of lightweight advanced technology carbon fibre wheels.

• Xpansiv Limited on an agreement with The Regional Voluntary Carbon Market Company (RVCMC) to provide the technology infrastructure for RVCMC’s carbon credit exchange.

• A wide range of corporate and private equity clients on the IP aspects of numerous high profile M&A transactions, including KKR’s $2.175bn purchase of Perpetual, and Guzman y Gomez’s IPO.

• The Sydney Children’s Hospital Foundation on a range of IP issues, including IP ownership structuring and overall brand strategy.

• A leading player in the AgTech space on a suite of interlinked agreements to fund, develop and commercialise genetically modified seed technology.